Objective-To clarify the significance of the humoral immune response triggered by the Mycobacterium tuberculosis (M.tb) 65 kDa heat shock protein
Abstract
Objective-To clarify the significance of the humoral immune response triggered by the Mycobacterium tuberculosis (M.tb) 65 kDa heat shock protein (hsp) in the pathogenesis of rheumatoid arthritis (RA). Methods-M.tb 65 kDa hsp-specific IgG, IgA, IgM, and IgG subclass antibodies in serum or synovial fluid (SF) of RA and other disease patients were determined by enzyme linked immunosorbent assay (ELISA). Results-RA patients did not show any characteristic increase in mycobacterial 65 kDa hsp-specific antibodies compared with healthy individuals. In contrast, antigen-specific IgG and IgG2 antibody titres in the serum of RA patients were significantly lower than those of patients with tuberculosis and normal controls. In addition, there was also no significant difference in antibody titre between the serum and SF of RA patients, nor was any significant difference found between the SF of RA and Reiter's patients. Conclusion patients with gouty arthritis or TB, and in normal subjects, but differences were significant only between RA and TB patients (p=0 036) and RA patients and normal controls (p = 0 048).
The antigen-specific IgG2:IgG4 ratio in the sera of RA patients was significantly less than that of TB patients (p = 0-014), as was that of patients with Reiter's disease (p = 0-021). In contrast, the IgG2:IgG4 ratios in TB patients were not significantly different from those of normal individuals or GA patients. The IgG2:IgG4 ratio in Reiter's patients was not significantly different from that of RA patients. Figure 2C shows the IgG2:IgG4 ratios in the groups studied. 
Discussion
Increased concentrations of IgG5-7 and IgA antibodies to the M. tb 65 kDa hsp protein have been found to be characteristic of patients with RA, being nearly three times those in the sera of normal subjects.7 Moreover, in one of these studies, the titres of antibodies in RA patients were significantly greater than those of tuberculosis patients. Decreased titres and frequencies of anti-M. tb 65 kDa IgG and IgG2 antibodies in RA patients were found in this study, but the reason for this is unknown. Disease activity or drug effects may not be implicated, because polyclonal hypergammaglobulinaemia and increased rheumatoid factor were present in RA patients compared with healthy individuals. In addition, antibody titres appeared not to be associated with disease severity (mild, moderate, or severe degree) in RA patients or with clinical pattern (fibrosis, cavity formation, and miliary dissemination) in TB patients (data not shown). Decreased titres of IgG2 antibodies resulting from the formation of immune complexes between IgG2 anti-M. tb 65 kDa antibodies and the 65 kDa hsp antigen are also unlikely. '5 In conclusion, neither high titres nor specific IgG subclass production of anti-M. tb 65 kDa hsp antibodies was observed in RA patients compared with patients with other diseases and healthy controls. Our failure to detect significant increases in anti-M. tb 65 kDa hsp antibodies in RA should not be interpreted as excluding the possibility of microbial immunity in the aetiology of RA, but anti-M. tb 65 kDa hsp antibodies clearly do not appear to be disease specific markers for RA and their relatively lower concentration is evidence against their playing a major role in the disease pathogenesis of RA. 
